Print

Cleveland Biolabs Inc. (CBLI) to Present at Biomedical Advanced Research and Development Authority (BARDA) and National Institute of Allergy And Infectious Diseases (NIAID) Sponsored Symposium on Development of Radiation Medical Countermeasures  
1/24/2013 9:26:54 AM

BUFFALO, N.Y., Jan. 24, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Company was invited to present at a symposium hosted by the Biomedical Advanced Research and Development Authority (BARDA) and National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The symposium, titled "Development of Radiation Medical Countermeasures for Licensure: Lessons Learned & Paths Forward" will include select product developers like CBLI, as well as U.S. government representatives of BARDA, NIAID, the U.S. Food and Drug Administration, the Department of Defense and the Centers for Disease Control and Prevention.
//-->